A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.

Chiara Paglino, Camillo Porta(University of Pavia), Carmine Tinelli(Policlinico San Matteo Fondazione), Alessandra Bearz(Centro di Riferimento Oncologico), Aristotelis Bamias(National and Kapodistrian University of Athens), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ilaria Imarisio(University of Pavia), Manuela Schmidinger(Medical University of Vienna), Roberto Sabbatini(Azienda Ospedaliero-Universitaria di Modena), Joaquim Bellmunt(Dana-Farber Cancer Institute), Bohuslav Melichar(Palacký University Olomouc)
PubMed
November 1, 2013
Cited by 3

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
|Cell|2017|2.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k